Last Close
Apr 02  •  04:00PM ET
4.07
Dollar change
+0.51
Percentage change
14.33
%
Index- P/E- EPS (ttm)-153.11 Insider Own98.44% Shs Outstand4.08M Perf Week175.00%
Market Cap22.54M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float- Perf Month129.94%
Enterprise Value13.42M PEG- EPS next Q- Inst Own4.45% Short Float- Perf Quarter-43.08%
Income-233.28M P/S173.38 EPS this Y- Inst Trans26.47% Short Ratio0.08 Perf Half Y-70.25%
Sales0.13M P/B0.35 EPS next Y- ROA-804.87% Short Interest0.13M Perf YTD-43.08%
Book/sh11.69 P/C2.09 EPS next 5Y- ROE-980.14% 52W High32.10 -87.32% Perf Year-80.62%
Cash/sh1.95 P/FCF- EPS past 3/5Y49.83% 54.21% ROIC-479.78% 52W Low1.03 295.15% Perf 3Y-95.85%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-56.34% -36.90% Gross Margin-474.81% Volatility52.50% 25.92% Perf 5Y-99.08%
Dividend TTM- EV/Sales103.23 EPS Y/Y TTM-303.51% Oper. Margin-22688.58% ATR (14)0.54 Perf 10Y-99.97%
Dividend Ex-Date- Quick Ratio10.02 Sales Y/Y TTM-92.43% Profit Margin-186197.06% RSI (14)75.48 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio10.02 EPS Q/Q-657.32% SMA20118.93% Beta1.47 Target Price45.00
Payout- Debt/Eq0.03 Sales Q/Q-98.58% SMA5070.21% Rel Volume5.08 Prev Close3.56
Employees14 LT Debt/Eq0.02 EarningsMar 31 AMC SMA200-51.62% Avg Volume1.61M Price4.07
IPOApr 09, 2010 Option/ShortNo / No EPS/Sales Surpr.- - Trades Volume8,186,630 Change14.33%
Date Action Analyst Rating Change Price Target Change
Aug-19-24Initiated H.C. Wainwright Buy $3
Apr-01-26 03:01PM
10:30AM
08:00AM
Mar-31-26 04:30PM
Mar-27-26 08:45AM
08:45AM Loading…
Mar-17-26 08:45AM
Feb-24-26 08:00AM
Feb-09-26 08:00AM
Jan-12-26 09:00AM
Dec-12-25 08:00AM
Dec-02-25 08:00AM
Nov-14-25 05:12PM
Oct-21-25 04:32AM
Oct-14-25 08:00AM
Oct-08-25 09:00AM
07:32AM Loading…
Sep-30-25 07:32AM
Sep-29-25 05:33PM
09:07AM
Sep-25-25 08:00AM
Sep-04-25 09:00AM
Aug-14-25 07:00AM
Jul-15-25 09:00AM
Jul-08-25 09:00AM
Jun-12-25 08:30AM
May-27-25 08:35AM
May-22-25 03:12PM
11:05AM
08:15AM
May-20-25 08:30AM
May-15-25 07:00AM
07:05PM Loading…
May-08-25 07:05PM
Apr-29-25 08:45AM
Apr-15-25 08:00AM
Apr-05-25 12:10PM
Apr-04-25 09:40AM
Apr-01-25 07:00AM
Mar-27-25 05:33PM
Mar-25-25 07:00AM
Mar-20-25 07:00AM
Mar-03-25 09:15AM
09:00AM
Feb-19-25 05:20PM
10:10AM
08:00AM
Feb-18-25 03:41PM
08:00AM
Feb-10-25 08:00AM
Jan-16-25 08:00AM
Jan-07-25 09:15AM
Jan-06-25 09:15AM
09:10AM
Dec-03-24 07:00AM
Nov-13-24 07:00AM
Oct-09-24 06:23PM
Sep-05-24 08:00AM
Aug-27-24 08:00AM
Aug-14-24 07:00AM
Aug-13-24 10:52PM
07:00AM
Aug-07-24 07:00AM
Jul-26-24 08:00AM
Jul-25-24 07:00AM
Jun-28-24 06:00AM
Jun-11-24 08:00AM
Jun-04-24 08:42AM
May-29-24 07:00AM
May-28-24 07:00AM
May-15-24 09:52AM
07:00AM
May-10-24 07:00AM
May-08-24 06:45AM
May-06-24 07:28AM
May-01-24 07:31AM
Apr-30-24 04:05PM
Apr-25-24 09:17AM
Apr-24-24 04:05PM
Apr-02-24 10:31AM
Mar-28-24 11:52PM
05:28PM
Feb-21-24 04:05PM
Jan-02-24 07:00AM
Nov-15-23 02:17PM
Nov-14-23 07:00AM
Nov-08-23 08:12AM
Nov-07-23 07:00AM
Aug-10-23 05:15PM
Aug-03-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-20-23 08:00AM
May-23-23 08:30AM
May-15-23 05:15PM
May-08-23 08:00AM
May-02-23 05:10PM
Apr-20-23 05:10PM
Apr-17-23 06:00PM
Apr-04-23 08:30AM
Mar-30-23 08:30AM
Mar-21-23 05:15PM
01:38PM
Axe Compute, Inc. engages in the application of artificial intelligence medicine and the provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment consists of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.